Could psychedelic mushrooms offer more than just mental healing? A new study suggests that psilocybin slows aging, not only in the mind, but potentially in the body as well.

A new study published in npj Aging suggests they might by extending cellular life and longevity in aged mice.

A First in Anti-Aging Psychedelic Research

Researchers investigated psilocin, the active metabolite of psilocybin, across two models:

1. Human cells (fetal lung and adult skin fibroblasts) treated with psilocin in vitro.

2. Aged female mice (~19 months old, equivalent to ~60–65 human years) receiving monthly psilocybin doses for 10 months.

These experiments are among the first to explore psilocybin’s systemic effects beyond the brain in a geroprotective context.

In Vitro: Cells Lived 30–57% Longer

• 29% increase in lifespan at 10 µM psilocin; up to 57% at 100 µM, compared to vehicle-treated controls.

• Slower onset of cellular senescence, reduced oxidative stress, preservation of telomere length, lowered expression of aging markers (p21, p16), and elevated DNA replication markers and antioxidant pathways like Nrf2 and SIRT1.

In Aged Mice: 30% Boost in Longevity and Health

• Monthly dosing (5 mg/kg initially, then 15 mg/kg) for 10 months.

• Survival rate was 80% in the psilocybin group vs. 50% in controls at study end.

• Treated mice also showed improved fur quality, reduced greying, and regrowth, signs of healthier aging.

Why These Findings Matter

• Shows that psilocybin may affect whole-body aging mechanisms, not just neuropsychiatric outcomes, delivering the first experimental support for the “psilocybin‑telomere hypothesis”.

• Relevance for late-life interventions: even starting treatment in older age appeared beneficial.

Possible Biological Mechanisms

• Activation of serotonin receptors (especially 5‑HT₂A) across various tissues, triggering longevity pathways like SIRT1.

• Preservation of telomere length and enhanced DNA repair signalling, hinting at multi-layered anti-aging effects.

• Potential epigenetic modulation, though further study is needed to confirm these effects and safety over time.

Limitations & Future Steps

• Preclinical only: results are from cells and mice, not yet tested in humans.

• Single-sex mouse study (female mice only).

• Unknown effects of long-term use on cancer risk, optimal dosing, or sex differences.

What’s Next?

Researchers emphasize the need for human trials, especially in older adults, to assess:

• Whether psilocybin improves biological aging markers in humans.

• Optimal treatment protocols (dose, frequency, age of initiation).

• Long-term safety, including any cancer-related risks.

Bottom Line

Psilocybin extended cell and mouse lifespan, in some cases by over 50%, suggesting it may protect against age-related decline when started late in life.

This landmark study opens a new frontier: psychedelics as geroprotectors, not just mental health tools. If validated in humans, it could confirm that psilocybin slows aging—positioning mushrooms as part of a novel anti-aging toolkit.

>>  Read full article HERE